# BRICKET: HCP commentary report

> 21 verified statements (8 from clinicians verified by NPI or staff page) from 11 commentary sources · 5 findings · updated Oct 28, 2026

## Report

- Trial: Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)
- NCT ID: NCT06578559
- Registry: https://clinicaltrials.gov/study/NCT06578559
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Phase: Phase 2
- Status: Completed
- Drugs: cetuximab
- Indications: Colorectal cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: 4ac064818a5a5e139af54cf85c6346d6cdedd8b24e3744f4310b4e1809d30052

## Counts

- HCP commentary sources screened: 25
- Sources cited by verified statements: 12
- Verified statements: 21
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 8
- Findings: 5
- People found in screened sources: 13
- Voices cited: 11
- Cited voices identity-verified: 10
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

BRICKET asks whether blood-test-guided encorafenib plus cetuximab retreatment benefits patients with BRAF V600E-mutated metastatic colorectal cancer after earlier benefit from the combination. Clinicians in the sources reviewed question retreatment, while support for continuing targeted therapy with a chemotherapy switch remains conditional. That alternative attracts interest; molecular selection and durability draw scrutiny. Treatment after progression remains an open research question. The sources reviewed for this edition place the trial’s main results at ESMO 2026.

## Open Medical Affairs question

What comparative evidence would justify continued EC with a chemotherapy switch, and what can BRICKET actually establish about ctDNA-guided treatment benefit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Continuing EC with a chemotherapy switch attracts support, explicitly as extrapolation
- F2. The negative reading concerns EC retreatment, with the conclusion kept tentative
- F3. Insufficient molecular selection and no testing benefit are different conclusions
- F4. Durability and small-study limitations challenge positive/negative labels
- F5. Research rationale persists without a claim of demonstrated retreatment benefit

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 8 | 8 | 1 | 6 | recorded | 3 |
| F2 | 4 | 4 | 4 | 3 | none recorded | 3 |
| F3 | 5 | 5 | 5 | 4 | none recorded | 4 |
| F4 | 4 | 3 | 3 | 1 | none recorded | 4 |
| F5 | 4 | 3 | 3 | 1 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 0 | 1 | 1 | 0 | 8 | 5 | 1 post or article | yes |
| F2 | 2 | 0 | 0 | 0 | 2 | 4 | 0 | 3 posts and articles, 1 registry | no |
| F3 | 3 | 0 | 0 | 0 | 2 | 5 | 0 | 4 posts and articles, 1 registry | yes |
| F4 | 0 | 2 | 0 | 1 | 1 | 4 | 1 | 2 posts and articles, 1 registry | yes |
| F5 | 2 | 0 | 0 | 1 | 1 | 4 | 0 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Objective Response Rate (ORR): F2 (1 shared claims)
- Secondary endpoints: F3 (1 shared claims), F4 (1 shared claims)
- Population and setting: F2 (3 shared claims), F3 (2 shared claims), F5 (2 shared claims)
- The comparison: F4 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F4 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. Durability and small-study limitations challenge positive/negative labels

An X post poses a cross-study interpretation question, rather than reporting a head-to-head comparison.

Source: X thread, 2026-10-24.

### F1. Continuing EC with a chemotherapy switch attracts support, explicitly as extrapolation

An X discussion poses an analogy as a question, rather than reporting a tested comparison.

Source: X thread, 2026-10-24.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 21 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 12 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

10 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response Rate (ORR) | discussed | 1 | 1 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 5 | 5 |
| The comparison | discussed | 1 | 1 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 1 | 1 |
| What ctDNA selection can—and cannot—show | discussed | 5 | 5 |
| Continuing EC while switching chemotherapy after progression | discussed | 5 | 1 |
| Evidence threshold and alternatives before routine adoption | discussed | 2 | 1 |
| Durability beyond positive/negative trial labels | discussed | 3 | 2 |
| Development rationale and post-BREAKWATER research questions | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 22 | 11 |
| Bluesky threads | 2 | 0 |
| Podcasts | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2020-06-30 to 2026-10-24
- Cited window: 2023-10-23 to 2026-10-24
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Single Arm Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients With BRAF V600E Mutated mCRC (BRICKET)
- Registry: NCT06578559 (https://clinicaltrials.gov/study/NCT06578559)
- Study IDs: BRICKET
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Collaborators: Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Completed
- Enrollment: 16 (actual)
- Start: 2024-07-23 (actual)
- Primary completion: 2026-05-12 (actual)
- Primary endpoint: Objective Response Rate (ORR) (8 months after the enrollment of the last patient.)
- Intervention: Cetuximab (drug)
- Intervention: Encorafenib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are X posts and quoted or linked material, not a representative sample of HCP practice. Reposts and duplicate quotations are not additional independent opinions.
- The search emphasized the trial identifier and names; unnamed references and transcription variants may have been missed. More than 2,000 sources without the trial name were not read, and one potentially relevant discussion was not fully assessed.
- No separate protocol was listed and no BRICKET results publication was identified. Reported numerical outcomes therefore describe what authors said, not a full appraisal of trial results.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No substantive safety or tolerability commentary was identified in the reviewed material. This does not establish an absence of toxicity or a favorable benefit–harm balance.
- Post dates do not establish presentation dates, changes of mind or disagreement across different settings.
- Cross-study PFS comparisons and biological explanations offered in the posts do not establish comparative efficacy or causal resistance mechanisms.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition, corrected 2026-10-29
  - Correction 2026-10-29: Corrected to match the delivered report: 10 people matched to verified clinician profiles (was 12); the sample findings.

Last checked for new commentary 2026-10-28. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (21 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (10 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/bricket-nct06578559
- Agents: POST https://www.erudio.com/api/orders with {"report": "bricket-nct06578559", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=bricket-06578559

## Cite

Erudio Health. BRICKET (NCT06578559): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/bricket-nct06578559

## Machine access

- JSON: https://www.erudio.com/reports/bricket-nct06578559.json
- Markdown: https://www.erudio.com/reports/bricket-nct06578559.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "bricket-06578559"}`